Basic Information
| LncRNA/CircRNA Name | PCSEAT |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | prostate cancer cell lines (293T, PC3, DU145, LNCaP, 22Rv1, RWPE-1, 769-P, 786-O,ACHN, Calu-1 and NCI-H1299) |
| Expression Pattern | up-regulated |
| Function Description | PCSEAT is specifically upregulated in human PCa tissues. Knockdown of PCSEAT results in the reduction of PCa cell growth and motility, and overexpression of PCSEAT reverses these phenotypes. Furthermore, bioactive PCSEAT is incorporated into exosomes and transmitted to adjacent cells, thus promoting cell proliferation and motility. Mechanistically, we found that PCSEAT promotes cell proliferation, at least in part by affecting miR-143-3p- and miR-24-2-5p-mediated regulation of EZH2, suggesting that PCSEAT and EZH2 competitively 'sponge' miR-143-3p and miR-24-2-5p. |
| Pubmed ID | 29803673 |
| Year | 2018 |
| Title | The Long Non-Coding RNA PCSEAT Exhibits an Oncogenic Property in Prostate Cancer and Functions as a Competing Endogenous RNA That Associates With EZH2 |
External Links
| Links for PCSEAT | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |